CTI BioPharma (NASDAQ:CTIC) Earns "Buy" Rating from Needham

Needham & Company LLC restated their buy rating on shares of CTI BioPharma (NASDAQ:CTIC – Get Rating) in a research note released on Wednesday morning, Benzinga reports. They currently have a $9.00 target price on the biopharmaceutical company’s stock. Several other research analysts also recently commented on CTIC. TD Cowen decreased their price objective on […]

Related Keywords

United States , America , Adamr Craig , Jamesk Fong , , Needham Company , Kestra Advisory Services , Fund Management Co , Prudential Financial Inc , Securities Exchange Commission , Biopharma Corp , America Corp , Proshare Advisors , Get Rating , Moderate Buy , Exchange Commission , Share Advisors , Fund Management , Advisory Services , Prudential Financial , Pharma Daily , Cti Biopharma , Nasdaq Ctic , Arctic , Medical , Reiterated Rating , Needham Company Llc ,